Oruka Therapeutics, Inc. ORKA Acquired in-process research and development
Acquired in-process research and development at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s acquired in-process research and development?
- Oruka Therapeutics, Inc. (ORKA) reported acquired in-process research and development of $29.15M in Q1 2026.
- How has Oruka Therapeutics, Inc.'s acquired in-process research and development changed year-over-year?
- Oruka Therapeutics, Inc.'s acquired in-process research and development increased by 46.3% year-over-year, from $19.93M to $29.15M.
- What does acquired in-process research and development mean?
- Represents cash outflows for the acquisition of in-process research and development projects from third parties. This metric reflects a company's strategy to supplement internal innovation pipelines through external asset purchases rather than organic development.